Table of Contents
Volume 4 | Issue 1
Publication Date: July 2002
Abstract
No Access
Pay-Per View
Full Text
Add to Cart
Editorial | ||
 13 |
Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer Sakkaraiappan Ramalingam, Chandra P. Belani |
|
Meeting Highlights | ||
16-20 |
Highlights From: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida Heather DeGrendele, Chandra P. Belani, Vinay K. Jain |
|
Research in Brief | ||
23-25 |
Activity of ZD1839 (Gefitinib, Iressa™) in Previously Treated Patients with Recurrent and Advanced Non–Small-Cell Lung Cancer Angelia D. Gibson, Mark Socinski, Chandra P. Belani, Vinay K. Jain |
|
Comprehensive Review | ||
26-34 |
Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Look Behind and Ahead Giovanni Selvaggi, Giorgio V. Scagliotti |
|
Original Contribution | ||
35-44 |
Use of Postoperative Radiotherapy for Node-Positive Non–Small-Cell Lung Cancer John Rescigno |
|
Commentary | ||
45-46 |
The Possible Use of Uniform PORT Doses Is Important in the SEER Analysis, but Undetected Selection Bias Remains an Issue James A. Bonner |
|
Original Contribution | ||
47-51 |
Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer Paul J. Hesketh, Christopher J. Nauman, Ann M. Hesketh, Janet LaPointe, Katrina Fogarty, Thein H. Oo, Derick H.M. Lau, Martin J. Edelman, David R. Gandara |
|
Case Report | ||
52-56 |
Hypersensitivity Pneumonitis in Advanced Non–Small-Cell Lung Cancer Patients Receiving Gemcitabine and Paclitaxel: Report of Two Cases and a Review of the Literature Fred J. Kudrik, M. Patricia Rivera, Paul L. Molina, Susan Maygarden, Mark A. Socinski |
|
Translational Medicine | ||
57-62 |
The Role of Farnesyltransferase Inhibitors in Lung Cancer Therapy Grace K. Dy, Alex A. Adjei |
|
Commentary | ||
63-64 |
Farnesyltransferase Inhibitors: A Promising Future in Cancer Treatment Fadlo R. Khuri, Victor Cohen |
|
